Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 77.61

+3.5%

Nov 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1905)	9/28/2007 12:30:16 AM
From: Jibacoa	Read Replies (2) of 3722

ALSE has been forming a little base at the 2.30 level. Today it was able to test its Aug 31- Sep 4 double top at the 2.79 level, but closed below it at 2.71, still up 6.27% on continued light volume of 15Ks. bigcharts.marketwatch.com ALSE announced on Monday that its independent Data Safety Monitoring Board has unanimously authorized expanding its PI/IIa trial of Cethrin in acute spinal cord injury. Authorization to administer a 9 mg dose in SCI had been given by the FDA in June & earlier by the Canadian Health. ALSE expects to complete enrollment in the trial by the end of the Yr.They are planning a PIIb/III to begin enrollment in early 2008. Cethrin is a recombinant protein intended to facilitate the re-growth of axons.It is delivered by a single application in patients that undergo decompression/stabilization surgery after spinal injury.It has been designated as an Orphan Drug by the FDA. In PI/IIa, Cethrin was given to patients that had suffered a complete thoracic or cervical injury & had no sensory or motor function below the level of the SCI. In the 37 patients that were treated,Cethrin was well tolerated & the treated patients showed better results, specially the patients that had sustained cervical injuries.(That last group showed a more pronounced response,6 to 7x greater than the full patient group treated with the standard of care reported in the literature.) The stock needs to close above 2.95 in order to get off from the DT coming from its June H at 3.52 bigcharts.marketwatch.com And then it would have to deal with the Aug-Sep 2006 double top at the 4.24 level bigcharts.marketwatch.com But if ALSE can get good results on its planned trials, which would be very good for patients with spinal cord injuries,the stock has plenty of room to run, since the 2000 H was 80.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next